Join us on 11 March 2020 for an exclusive London Advanced Therapies ATN, powered by MedCity event on ATMP manufacturing in the UK, with leading academic and industry expert panellists.
Why ATMP Manufacturing?
The UK is one of the leading sources of research and development in advanced therapies, with over 900 therapeutic developers, 1,060 clinical trials and 14 approved ATMPs (ARM and BIA 2019). With 25 manufacturing facilities across the UK, we are competitively positioned as a leading global hub in the field, but key challenges remain to be addressed, particularly when it comes to manufacturing at scale.
Investment, funding opportunities, viral vector manufacturing capacity and the right skills and talent are all challenges facing both academia and industry, whose capacity to translate research into clinical products is at critical levels.
This event will bring together leading academic and industry experts to discuss the current state of play in this landscape, along with the challenges and the way forward. We will also look at how to translate current ATMP manufacturing capabilities into clinical excellence, and the important role investment is playing in the race for global leader status.
- 16:30 Registration, tea and coffee
- 17:00 Opening Remarks – Dr Francesca Gliubich, Director of London Advanced Therapies
- 17:10 Session 1: The ATMP manufacturing landscape in the UK and the current challenges
- 17:10 – Keynote – Ian McCubbin, OBE, Chair RoslinCT and Manufacturing advisory group Innovate
- 17:25 – Panel Discussion
- Prof Uta Griesenbach, Imperial College London
- Matthew Durdy, CBO, Cell and Gene Therapy Catapult
- Dr James Miskin, CTO, Oxford Biomedica
- Prof Farzin Farzaneh, King’s College London
- Peter Coleman, CEO, Cobra Biologics
- Dr Mike Scott, COO, Advent Bioservices
- 18:10 Session 2: Translating the UK ATMP manufacturing capabilities to clinical excellence and the role of investment
- 18:10 – Keynote – Dr Eliot Forster, CEO, F- Star and Chairman, MedCity
- 18:25 – Panel Discussion
- Prof Emma Morris, UCL and UCLH
- Dr Jacqueline Barry, CCO, Cell and Gene Therapy Catapult
- Prof Andrew Baker, University of Edinburgh
- Prof Adrian Thrasher, UCL
- Dr Catriona Crombie, LifeArc
- 19:10 Closing Remarks – Dr Pamela Tranter, Head, Translational Research, UCL
- 19:20 – 20:30 Networking reception
The Advanced Therapies Network aims to support networking opportunities and knowledge exchange between academic organisations, life sciences companies and investors in this area.
Estimated to have a global market worth of £9bn to 14bn by 2025, advanced therapies is a novel approach to medicine that uses experimental techniques to treat a wide range of conditions, including cancer and rare diseases. There are over 130 advanced therapies companies in the UK, with 60% residing in the greater south east of England, including university spinouts such as Orchard Therapeutics, Autolus, Cell Medica, GammaDelta Therapeutics and Quethera.
Aims of the Advanced Therapies Network (ATN)
The Advanced Therapies Network was launched in November 2018. Part of London Advanced Therapies and funded by the Research England, it brings together collective expertise in this area to accelerate the progression for patient benefit. The ATN is running a series of events to discuss the challenges to commercialisation in the sector and provide networking opportunities. The events cover subjects such as clinical trials, investment, data and reimboursement.